AtriCure, Inc.
$28.79
▲
2.68%
2026-04-21 05:28:00
www.atricure.com
NGM: ATRC
Explore AtriCure, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.51 B
Current Price
$28.79
52W High / Low
$43.18 / $27.26
Stock P/E
—
Book Value
$9.88
Dividend Yield
—
ROCE
-1.65%
ROE
-2.4%
Face Value
—
EPS
$-0.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,350
Beta
1.43
Debt / Equity
15.54
Current Ratio
3.96
Quick Ratio
2.99
Forward P/E
76.38
Price / Sales
2.67
Enterprise Value
$1.32 B
EV / EBITDA
118.65
EV / Revenue
2.46
Rating
Buy
Target Price
$47.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alcon Inc. | $77.24 | — | $30.37 B | 0.45% | 4.77% | 4.5% | $81.92 / $56.44 | $45.2 |
| 2. | Envista Holdings Corporation | $27.85 | 97.1 | $4.56 B | — | 4.89% | 1.56% | $30.42 / $14.72 | $18.96 |
| 3. | Align Technology, Inc. | $194.19 | 34.46 | $14 B | — | 13.57% | 10.39% | $208.31 / $122 | $56.74 |
| 4. | Harvard Bioscience, Inc. | $6.99 | — | $30.92 M | — | 0.17% | -1.47% | $9.46 / $2.81 | $3.07 |
| 5. | Lucyd, Inc | $1.07 | — | $6.68 M | — | -93.41% | -83.6% | $4.97 / $0.95 | $1.65 |
| 6. | KORU Medical Systems, Inc. | $4.26 | — | $200.78 M | — | -14.86% | -15.58% | $6.61 / $2.08 | $0.37 |
| 7. | GlucoTrack, Inc. | $0.78 | — | $1.55 M | — | -524.96% | 381.2% | $15.9 / $0.62 | $3.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 140.5 M | 134.27 M | 136.14 M | 123.62 M | 124.28 M |
| Operating Profit | 2.49 M | 0.21 M | -6.19 M | -5.95 M | -14.52 M |
| Net Profit | 1.76 M | -0.27 M | -6.19 M | -6.75 M | -15.57 M |
| EPS in Rs | 0.03 | -0.01 | -0.12 | -0.13 | -0.31 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 534.53 M | 465.31 M | 399.25 M | 330.38 M |
| Operating Profit | -9.45 M | -40.01 M | -26.68 M | -42.67 M |
| Net Profit | -11.45 M | -44.7 M | -30.44 M | -46.47 M |
| EPS in Rs | -0.23 | -0.88 | -0.6 | -0.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 654.18 M | 609.33 M | 613.93 M | 585.45 M |
| Total Liabilities | 162.24 M | 148.36 M | 147.76 M | 128.69 M |
| Equity | 491.94 M | 460.97 M | 466.17 M | 456.75 M |
| Current Assets | 322.52 M | 267.83 M | 266.25 M | 215.21 M |
| Current Liabilities | 81.52 M | 73.42 M | 74.57 M | 58.39 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 57.33 M | 12.2 M | 4.48 M | -22.14 M |
| Investing CF | -14.55 M | 30.23 M | 21.82 M | 44.01 M |
| Financing CF | 1.18 M | -3.6 M | -0.03 M | -7.06 M |
| Free CF | 42.28 M | -11.26 M | -37.51 M | -39.02 M |
| Capex | -15.05 M | -23.46 M | -42 M | -16.88 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 16.55% | 20.84% | — | — |
| Earnings Growth % | -46.85% | 34.49% | — | — |
| Profit Margin % | -9.61% | -7.62% | -14.06% | — |
| Operating Margin % | -8.6% | -6.68% | -12.92% | — |
| Gross Margin % | 74.69% | 75.23% | 74.44% | — |
| EBITDA Margin % | -3.98% | -2.03% | -8.93% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.